Apr 29, 2024 04:23PM
Apr 29, 2024 04:01PM
Mar 13, 2024 04:02PM
Feb 5, 2024 05:17PM
Feb 5, 2024 05:15PM
Feb 5, 2024 04:49PM
Feb 5, 2024 04:46PM Incyte (INCY) Acquires Rights to Tafasitamab from MorphoSys (MOR)
Feb 5, 2024 04:46PM
Feb 5, 2024 11:47AM
Jan 30, 2024 05:42AM
Jan 30, 2024 03:15AM
Dec 11, 2023 03:47AM
Dec 10, 2023 07:31PM
Nov 20, 2023 04:30PM MorphoSys AG (MOR) Reports Phase 3 Study of Pelabresib in Myelofibrosis Demonstrates Statistically Significant Improvement in Spleen Volume Reduction and Strong Positive Trend in Symptom Reduction
Nov 20, 2023 04:30PM
Nov 15, 2023 04:01PM
Nov 2, 2023 09:45AM
Sep 12, 2023 04:54PM
Sep 12, 2023 04:20PM
Aug 9, 2023 04:01PM
May 3, 2023 04:01PM MorphoSys AG Reports First Quarter 2023 Financial Results
Apr 16, 2023 03:01PM
Mar 15, 2023 04:03PM
Jan 5, 2023 06:13AM
Jan 5, 2023 06:00AM
Nov 16, 2022 04:01PM
Nov 3, 2022 09:25AM
Oct 21, 2022 06:00AM MorphoSys Reports Preliminary Q3 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022
Sep 28, 2022 04:03PM
Sep 28, 2022 04:01PM
Aug 31, 2022 04:01PM
Aug 3, 2022 04:01PM
Jul 26, 2022 05:53AM
Jul 26, 2022 05:40AM
Jun 14, 2022 04:04PM MorphoSys AG (MOR) and HIBio Enter Into Equity Participation and License Agreements for Felzartamab and MOR210
Jun 14, 2022 04:01PM
Jun 13, 2022 04:01PM
Jun 13, 2022 04:01PM
May 12, 2022 10:45AM
May 4, 2022 04:01PM
Mar 22, 2022 04:46PM
Mar 22, 2022 04:45PM MorphoSys and Incyte Announce Swissmedic Temporary Approval of Minjuvi(R) (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with r/r DLBCL
Mar 16, 2022 04:07PM
Mar 15, 2022 04:40PM
Dec 13, 2021 05:22AM
Dec 11, 2021 12:00PM
Dec 11, 2021 12:00PM
Nov 9, 2021 04:20PM
Nov 4, 2021 04:20PM MorphoSys Presents Interim Results from M-PLACE Study with Felzartamab during American Society of Nephrology Annual Meeting
Nov 4, 2021 09:30AM

322,174 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All